Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Scleritis is often associated with autoimmune and rheumatic conditions, such as rheumatoid arthritis and lupus. The prevalence of these underlying conditions significantly influences the market for scleritis treatment, with a focus on addressing the systemic factors contributing to inflammation.
Scleritis has been reported overlaps patients of different age group, but tends to be more frequent in adults. It is paramount to recognize patient demographics with scleritis, especially with regard to age distribution and gender, in order to shape the treatment policy based on these results and foster any potential trends in the market for specialized therapies.
The lymphatic system organization and role modulation in scleritis assists development of specific, targeted treatment attitudes. The discovery of some specific cytokines and inflammatory mediators as reasons for scleritis help pharmaceutical companies to develop biologic drugs and immunomodulators for the treatment of scleritis.
The market of scleritis treatments is impacted by ophthalmic innovations like vision technologies and laboratory examination tools. More accurate diagnostics, earlier detection and surveillance of scleritis translate to improved outcomes for patients, thus, highlighting the efforts made in the field of modern ophthalmic equipment.
One of the frequently used therapy drugs in scleritis drugs is corticosteroids. The key function is to bring the inflammation down. The market reflects adventurousness in steroid preparations, dosage patterns and other anti-inflammatory trends that prevent reliance on long-term steroid therapy and side effects minimisation.
One of the major therapeutic agents in treating scleritis includes immunosuppressive medications; therefore, these are particularly helpful in the treatment of the severe or recurring inflammation. The advancement of drug development in the field of immunosuppressive is one of the key factors that affects the market of scleritis treatment as the drugs are targeted towards high efficacy and low risk.
The various subtypes which scleritis can present as, anterior, posterior, or necrotizing, can be found among the different forms. The difference between the characteristics of distinct types and the therapies needed for each subtype can be used to refine market strategies and focus on personalizing approach for different patient segments according to their type.
Ongoing clinical trials and research initiatives in the field of scleritis contribute to the market by expanding the understanding of the disease and exploring novel therapeutic options. Research funding drives innovation, supporting the development of new treatments and interventions.
The extent of health insurance coverage for scleritis treatments affects patient access to medical interventions. Comprehensive insurance policies that cover immunosuppressive medications, biologics, and ophthalmic procedures impact the overall demand for scleritis care.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | Â 7.8% |
Scleritis Market Highlights:
Scleritis Market Overview
Scleritis Market Size was valued at USD 2.9 Billion in 2023. The Global Scleritis industry is projected to grow from USD 3.08 Billion in 2024 to USD 4.99 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period (2024 - 2032).
Scleritis is a medical condition that causes painful inflammation of sclera (white part of the eye). In some severe cases, the disease is reported to cause loss of vision, i.e., by affecting episclera and sclera. Thus, its timely diagnosis and treatment are necessary against scleritis. Focal redness or violaceous discoloration, scleral thickening, late scleral, and scleral necrosis are some of the prominent symptoms associated with the disease.
It is established that more than 50% of scleritis cases are associated with autoimmune disease, including rheumatoid arthritis. The prevalence of rheumatoid arthritis is increasing and, thus, the susceptible scleritis patient population. It is suggestive that the prevalence of rheumatoid arthritis was about 0.5–1.0% within regional boundaries of North America and Northern Europe. This scleritis market is indicating a positive market growth during the forecast period, 2022–2030.
Moreover, factors such as the growing aging population and increasing per capita healthcare expenditure boost the market growth. However, lack of awareness in the middle-income countries and the absence of targeted treatment is estimated to restraint the market growth during the forecast period.
Scleritis Market Segmentation
Scleritis market has been segmented into type, diagnostic test & treatment, end-user, and region.
The scleritis market, based on type, has been segmented into anterior scleritis and posterior scleritis. The anterior scleritis segment is further segmented into diffuse scleritis, nodular scleritis, and necrotizing scleritis.
The scleritis global market, by diagnostic test & treatment, has been divided into diagnostic tests and treatment. The diagnostic test market is further segmented into ultrasonography, complete blood count, biopsy, others.
The treatment segment is sub-divided into medication and surgery. The medication segment is further classified into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further classified into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.
The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.
Scleritis Market Key Players
- Amgen
- Amneal Pharmaceuticals LLC
- Baxter International Inc.
- Boehringer Ingelheim
- Fresenius Kabi USA, LLC
- Jubilant Cadista Pharmaceuticals Inc.
- Mylan Pharmaceuticals Inc.
- Novartis Pharmaceuticals
- Perrigo Company
- Roxane Laboratories, Inc.
- Sandoz Inc.
- Shanghai Henlius Biotech
- Teva Pharmaceuticals USA, Inc.
- West-Ward Pharmaceuticals
- Zydus Pharmaceuticals (USA) Inc.
Regional Market Summary
Geographically, the Americas is projected to lead the scleritis market. This can be attributed due to the presence of well-developed healthcare infrastructure and the increasing prevalence of scleritis within the Americas.
Europe is expected to hold the second-largest share of the scleritis market owing to government support and the presence of developed countries such as the UK, Germany, and France within the region.
The scleritis market in Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia-Pacific. The region is estimated to grow with the highest CAGR. High prevalence of scleritis, growing geriatric population, and increasing penetration of market players boost the regional market. In India, the mean age of scleritis patients is estimated to be about 55. This susceptible age group is expanding, which is growing the treatment-seeking patient pool.
The Middle East & Africa is anticipated to hold the least share of the market owing to the presence of poor economies, stringent government regulations, and low per capita income in Africa. Within the region, the Middle East is projected to lead the market owing to developed healthcare infrastructure and the presence of economies such as Saudi Arabia, Kuwait, and Dubai.
Scleritis Market, by Type
- Anterior Scleritis
- Diffuse Scleritis
- Nodular Scleritis
- Necrotizing Scleritis
- Posterior Scleritis
Scleritis Market, by Diagnostic Test & Treatment
- Diagnostic Test
- Ultrasonography
- Complete Blood Count
- Biopsy
- Others
- Treatment
- Medication
- Corticosteroid
- Difluprednate
- Prednisolone
- Others
- Nonsteroidal Anti-Inflammatory Drugs
- Aspirin
- Ibuprofen
- Others
- Immunosuppressive Drugs
- Methotrexate
- Mycophenolate
- Others
- Corticosteroid
- Surgery
- Medication
Scleritis Market, by End User
- Hospitals & Clinics
- Diagnostic Centers
- Academic & Research Organizations
Scleritis Market, by Region
- Americas
- North America
- US
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Pharmaceutical companies
- Medical devices companies
- Contract research organizations
- Contract manufacturing organizations
- Research and development organization
- Academics and research institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
